A US appeals court has ruled that Regeneron and Sanofi’s Praluent can stay on the market while they appeal a patent case from rival Amgen that blocked them from selling it. Last month ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

The U.S. Patent Office has published updated examination guidelines regarding the enablement requirement in view of the ...

In a unanimous ruling, the Supreme Court of the United States (SCOTUS) addressed the enablement requirement under Section 112 of the Patent Act, placing this into sharper focus with the Amgen v.

Recombinant Dna Technology Market Set To Witness Significant Growth By 2024-2031: Sanofi , Pfizer, Inc., Amgen, Inc. Recombinant Dna technology market is expected to reach USD 327.63 Bn by 2031, ...

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...

ASCO: With first-in-class win, Sanofi's Sarclisa looks to step out of ... There’s also a combination of Sarclisa with Amgen’s Kyprolis, lenalidomide and dexamethasone (KRd).

Amgen (AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs rocatinlimab and ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...

Amgen shares fell 4.5% after the biotech revealed disappointing study results for two closely watched drug candidates. The company, in a call with analysts and investors, reported positiv ...

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...